Try our Advanced Search for more refined results

Jones et al v. Pfizer, Inc. et al

  1. August 11, 2015

    Robbins Geller Gets $60M In $400M Pfizer Class Action Deal

    A New York federal judge awarded $60 million in attorneys' fees Tuesday to Robbins Geller Rudman & Dowd LLP, lead counsel in a shareholder class action accusing Pfizer Inc. of misleading investors about off-label marketing of various drugs, less than two-thirds of the $94 million the firm had asked for.

  2. July 31, 2015

    $400M Pfizer Class Action Deal Gets OK From Judge

    A New York federal judge on Thursday granted final approval of a $400 million settlement that ends a class action accusing Pfizer Inc. of misleading investors about illegal off-label drug marketing, though some investors may not get much with a recovery rate of 15 cents per share.

  3. June 08, 2015

    Pfizer Plaintiffs Defend Robbins Geller Fees In $400M Deal

    Plaintiffs pushing for final approval of a $400 million settlement with Pfizer Inc. in an off-label marketing class action urged a New York federal judge on Friday to overrule objections to a $94 million fee request by lead counsel from Robbins Geller Rudman & Dowd LLP.

  4. May 19, 2015

    Robbins Geller $94M Fee In Pfizer Suit Too High, Judge Told

    Robbins Geller Rudman & Dowd LLP is getting greedy with its $94 million fee request in a $400 million settlement with Pfizer Inc., one of the investor plaintiffs complained to a New York federal judge Monday.

  5. May 06, 2015

    Robbins Geller Seeks $94M Fees In $400M Pfizer Class Deal

    Robbins Geller Rudman & Dowd LLP, lead counsel in a shareholder class action accusing Pfizer Inc. of misleading investors about the off-label marketing of various drugs, asked a New York federal judge on Wednesday to approve $94 million in attorneys' fees to be paid out of the $400 million settlement.

  6. March 16, 2015

    Pfizer's $400M Class Action Settlement Gets Early Nod

    A New York federal judge on Monday granted early approval to a $400 million settlement ending a class action lawsuit accusing Pfizer Inc. of misleading investors about illegal off-label drug marketing, after attorneys revised notices to class members clarifying details about the litigation.

  7. February 26, 2015

    $400M Pfizer Class Action Settlement On Track For Approval

    A proposed $400 million deal to resolve a class action lawsuit accusing Pfizer Inc. of misleading investors about illegal off-label drug marketing was put on track for approval on Thursday, but not before a Manhattan federal judge asked pointed questions about the value of the deal and demanded a fresh round of opt-out notices for investors. 

  8. January 27, 2015

    Pfizer Strikes $400M Deal To End Shareholder Suit

    Pfizer Inc. has reached a $400 million settlement to avoid an upcoming trial in a class action claiming the company misled investors about an alleged off-label drug marketing scheme, the pharmaceutical giant said Tuesday in a regulatory filing.

  9. October 30, 2014

    Convicted Ex-Pfizer Manager Won't Testify In Off-Label Suit

    A former Pfizer Inc. sales manager who was convicted in 2009 for illegal drug marketing can't be forced to testify in a class action suit alleging the pharmaceutical giant concealed a broader fraud scheme from investors, a New York federal judge ruled Thursday.

  10. November 29, 2011

    Pfizer Told To Cough Up Docs In Drug Marketing Action

    A New York federal judge on Tuesday ordered Pfizer Inc. to turn over about 32 million pages of documents to class action lawyers who claim the company broke securities laws by hiding illegal off-label drug marketing.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!